Published in Antimicrob Agents Chemother on April 01, 1986
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev (1995) 8.81
Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother (1988) 4.79
Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother (1993) 3.79
Overview of medically important antifungal azole derivatives. Clin Microbiol Rev (1988) 3.33
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother (1996) 3.20
The gene encoding phosphoribosylaminoimidazole carboxylase (ADE2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid. Infect Immun (1993) 1.96
Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother (1989) 1.93
Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol (1998) 1.89
Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother (1988) 1.85
Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. Antimicrob Agents Chemother (1989) 1.78
Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans. Proc Natl Acad Sci U S A (1994) 1.72
Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Chemother (1989) 1.66
Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans. Antimicrob Agents Chemother (1991) 1.37
Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Antimicrob Agents Chemother (1995) 1.35
Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans. Antimicrob Agents Chemother (1988) 1.31
In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum. Antimicrob Agents Chemother (1990) 1.31
Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother (1987) 1.27
Treatment of experimental disseminated candidiasis with cilofungin. Antimicrob Agents Chemother (1989) 1.26
Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. Antimicrob Agents Chemother (1990) 1.24
Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob Agents Chemother (1998) 1.23
Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B. Antimicrob Agents Chemother (1994) 1.13
Pharmacokinetics of fluconazole in cerebrospinal fluid and serum of rabbits: validation of an animal model used to measure drug concentrations in cerebrospinal fluid. Antimicrob Agents Chemother (1994) 1.13
Tissue penetration of antifungal agents. Clin Microbiol Rev (2014) 1.13
Uptake of itraconazole by alveolar macrophages. Antimicrob Agents Chemother (1993) 1.12
Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum. Antimicrob Agents Chemother (2005) 1.07
Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis. Antimicrob Agents Chemother (1994) 1.04
Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits. Antimicrob Agents Chemother (1991) 1.02
Treatment of murine coccidioidal meningitis with SCH39304. Antimicrob Agents Chemother (1990) 0.99
In vitro models for studying toxicity of antifungal agents. Antimicrob Agents Chemother (1992) 0.97
Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis. Antimicrob Agents Chemother (2000) 0.97
Reflections on the approach to treatment of a mycologic disaster. Antimicrob Agents Chemother (2013) 0.96
Fluconazole in the treatment of Candida-associated denture stomatitis. Antimicrob Agents Chemother (1988) 0.92
Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography. Antimicrob Agents Chemother (1995) 0.86
Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med (2014) 0.85
Fluconazole (UK-49,858) treatment of candidiasis in normal and diabetic rats. Antimicrob Agents Chemother (1989) 0.83
Itraconazole as maintenance treatment for cryptococcal meningitis in the acquired immune deficiency syndrome. Br Med J (Clin Res Ed) (1988) 0.81
In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemother (2004) 0.81
Comparison of fluconazole and SDZ89-485 for therapy of experimental murine coccidioidomycosis. Antimicrob Agents Chemother (1990) 0.80
In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans. Antimicrob Agents Chemother (1998) 0.77
Transcriptomic analysis of Ustilago maydis infecting Arabidopsis reveals important aspects of the fungus pathogenic mechanisms. Plant Signal Behav (2013) 0.75
Phaeohyphomycotic cyst caused by a recently described species, Phaeoannellomyces elegans. J Clin Microbiol (1987) 0.75
Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol (1966) 27.11
Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother (1976) 8.54
Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis (1972) 7.47
Azole resistance in Candida albicans. Sabouraudia (1984) 6.23
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis (1969) 5.58
Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol (1980) 4.28
Strategies in the treatment of systemic fungal infections. N Engl J Med (1980) 2.89
Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med (1983) 2.35
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
Antifungal agents useful in therapy of systemic fungal infections. Annu Rev Pharmacol Toxicol (1983) 2.11
Cryptococcemia. Medicine (Baltimore) (1983) 2.10
Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother (1985) 2.02
Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid. Antimicrob Agents Chemother (1981) 1.77
Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole. J Infect Dis (1982) 1.58
Miconazole therapy for treatment of fungal infections in cancer patients. Antimicrob Agents Chemother (1979) 1.41
Treatment of paracoccidioidomycosis with ketoconazole: a three-year experience. Am J Med (1983) 1.30
Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis. Am J Med (1983) 1.26
Urinary tract infections due to Candida albicans. Rev Infect Dis (1983) 1.19
Oral ketoconazole. An effective and safe treatment for dermatophytosis. Arch Dermatol (1981) 1.11
Bone and joint coccidioidomycosis treated with miconazole. Am Rev Respir Dis (1979) 0.88
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev (1995) 8.81
Experimental bacterial endocarditis. I. Colonization of a sterile vegetation. Br J Exp Pathol (1972) 8.33
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Chemotherapy of experimental streptococcal endocarditis. I. Comparison of commonly recommended prophylactic regimens. J Clin Invest (1973) 5.49
Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. J Bacteriol (1993) 5.14
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol (1980) 4.28
Cryptococcus neoformans mating and virulence are regulated by the G-protein alpha subunit GPA1 and cAMP. Genes Dev (1997) 4.28
Experimental bacterial endocarditis. II. Survival of a bacteria in endocardial vegetations. Br J Exp Pathol (1972) 4.03
Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis (2001) 4.01
Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest (1985) 3.98
Experimental bacterial endocarditis. IV. Structure and evolution of very early lesions. J Pathol (1975) 3.96
Experimental bacterial endocarditis. 3. Production and progress of the disease in rabbits. Br J Exp Pathol (1973) 3.79
Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother (1993) 3.79
Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med (1996) 3.76
Specific amino acid (L-arginine) requirement for the microbiostatic activity of murine macrophages. J Clin Invest (1988) 3.69
Urease as a virulence factor in experimental cryptococcosis. Infect Immun (2000) 3.53
Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans. Mol Cell Biol (2001) 3.11
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis (1998) 3.09
Chemotherapy of experimental streptococcal endocarditis. IV. Further observations on prophylaxis. J Clin Invest (1975) 3.03
Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol (2001) 3.02
The neuroleptic malignant syndrome. Arch Intern Med (1982) 2.98
Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest (1990) 2.91
Infection due to Actinobacillus actinomycetemcomitans: 15 cases and review. Rev Infect Dis (1989) 2.89
International health and internal medicine residency training: the Duke University experience. Am J Med (1995) 2.83
In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother (1997) 2.76
Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA (1990) 2.61
Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli. Antimicrob Agents Chemother (1980) 2.35
Prevention of Bacterial Endocarditis. A statement for health professionals by the Committee on Rheumatic Fever and Infective Endocarditis of the Council on Cardiovascular Disease in the Young. Circulation (1984) 2.33
Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol (1998) 2.30
RAS1 regulates filamentation, mating and growth at high temperature of Cryptococcus neoformans. Mol Microbiol (2000) 2.30
Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis (2006) 2.17
Cryptococcemia. Medicine (Baltimore) (1983) 2.10
Opportunistic infections and Kaposi's sarcoma in homosexual men. N Engl J Med (1981) 2.09
Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity. J Immunol (1986) 2.06
The G-protein beta subunit GPB1 is required for mating and haploid fruiting in Cryptococcus neoformans. Mol Cell Biol (2000) 2.03
Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci. JAMA (1989) 2.03
Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother (1985) 2.02
Chemotherapy of experimental streptococcal endocarditis. II. Synergism between penicillin and streptomycin against penicillin-sensitive streptococci. J Clin Invest (1974) 1.96
Identification of the MATa mating-type locus of Cryptococcus neoformans reveals a serotype A MATa strain thought to have been extinct. Proc Natl Acad Sci U S A (2000) 1.96
Antibiotic tolerance among clinical isolates of bacteria. Antimicrob Agents Chemother (1986) 1.95
Neurotoxicity of human eosinophils. Proc Natl Acad Sci U S A (1979) 1.89
The weight of medical knowledge. N Engl J Med (1978) 1.87
Purification of human eosinophil-derived neurotoxin. Proc Natl Acad Sci U S A (1981) 1.85
Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J Infect Dis (1987) 1.85
Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob Agents Chemother (1985) 1.78
Current practice in prevention of bacterial endocarditis. Br Heart J (1975) 1.78
Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. Antimicrob Agents Chemother (1989) 1.78
Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. EMBO J (2000) 1.76
The STE12alpha homolog is required for haploid filamentation but largely dispensable for mating and virulence in Cryptococcus neoformans. Genetics (1999) 1.75
Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans. Proc Natl Acad Sci U S A (1994) 1.72
Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. Genes Dev (2001) 1.72
Single and multiple pyogenic liver abscesses. Natural history, diagnosis and treatment, with emphasis on percutaneous drainage. Medicine (Baltimore) (1984) 1.68
Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 1.66
A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function. J Bacteriol (1999) 1.65
Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol Cell Biol (1999) 1.64
Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. Drugs (1997) 1.63
Fever of unknown origin--reexamined and redefined. Curr Clin Top Infect Dis (1991) 1.63
Differential diagnosis of acute meningitis. An analysis of the predictive value of initial observations. JAMA (1989) 1.58
Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole. J Infect Dis (1982) 1.58
Protective role of complement in experimental Escherichia coli endocarditis. Infect Immun (1977) 1.57
Chemotherapy of experimental streptococcal endocarditis. 3. Failure of a bacteriostatic agent (tetracycline) in prophylaxis. J Clin Pathol (1974) 1.56
Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Ann Intern Med (1983) 1.56
Disseminated infection with rapidly growing mycobacteria. Clin Infect Dis (1993) 1.55
Dominant selection system for use in Cryptococcus neoformans. J Med Vet Mycol (1997) 1.54
Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis (1999) 1.51
Fungal meningitis. Semin Neurol (2000) 1.50
Cryptococcus neoformans gene expression during experimental cryptococcal meningitis. Eukaryot Cell (2003) 1.49
Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus. J Infect Dis (1981) 1.48
Two cyclophilin A homologs with shared and distinct functions important for growth and virulence of Cryptococcus neoformans. EMBO Rep (2001) 1.46
Disseminated zygomycosis: report of four cases and review. Rev Infect Dis (1989) 1.45
Effect of immunization on susceptibility to experimental Streptococcus mutans and Streptococcus sanguis endocarditis. Infect Immun (1978) 1.44
Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother (2000) 1.42
Mitochondrial iron loss from leukemia cells injured by macrophages. A possible mechanism for electron transport chain defects. J Immunol (1988) 1.41
Signal transduction pathways regulating differentiation and pathogenicity of Cryptococcus neoformans. Fungal Genet Biol (1998) 1.41
Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci. Antimicrob Agents Chemother (1982) 1.41
Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet (1988) 1.38
Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob Agents Chemother (2001) 1.37
Apparent failures of endocarditis prophylaxis. Analysis of 52 cases submitted to a national registry. JAMA (1983) 1.35
Chemotherapy of experimental streptococcal endocarditis. VI. Prevention of enterococcal endocarditis. J Lab Clin Med (1977) 1.31
Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis (1985) 1.31
Structure-in vitro activity relationships of pentamidine analogues and dication-substituted bis-benzimidazoles as new antifungal agents. Antimicrob Agents Chemother (1998) 1.29
Influence of agglutinating antibody in experimental cryptococcal meningitis. Br J Exp Pathol (1981) 1.29
The risk of stroke and death in patients with aortic and mitral valve endocarditis. Am Heart J (2001) 1.29
Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother (1987) 1.27